Loading patent…
AssigneesThe Schepens Eye Research Institute, Inc., The Regents of the University of California
InventorsBenjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Estimating the term…
The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
A method for treating ocular discomfort comprising topically administering to the ocular surface of an individual in need an effective amount of a pharmaceutical composition comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT (SEQ ID NO:4) in an ophthalmically acceptable vehicle.
Dependencies are inferred from the claim text.